DuPont today announced it signed an agreement to acquire Donatelle Plastics for an undisclosed amount.
The transaction is expected to close in the third quarter of 2024 and is subject to the satisfaction of customary closing conditions and receipt of regulatory approvals. The financial details of the deal were not disclosed.
“Our healthcare strategy is focused on offering a comprehensive suite of solutions for customers in high-growth therapeutic areas,” said Jon Kemp, president of DuPont Electronics & Industrial (E&I). “Donatelle Plastics Incorporated will be the second acquisition, following Spectrum last year, that will deepen our expertise in the medical device market segments and enhance our position as a partner of choice for our customers.”
Donatelle Plastics was founded in 1967 with headquarters in New Brighton, Minnesota. It provides injection molding expertise and component manufacturing for leading original equipment manufacturers. DuPont says Donatelle has a strong financial growth profile aligned to attractive therapeutic areas such as electrophysiology, drug delivery, diagnostics, cardiac rhythm management, neurostimulation and orthopedic extremities.
The acquisition of Donatelle Plastics will bring complementary advanced technologies and capabilities to DuPont’s offerings, including medical device injection molding, liquid silicone rubber processing, precision machining, device assembly and tool building.
“We’re excited for this next chapter in Donatelle’s journey and for our team of highly talented and skilled employees to join DuPont,” said Treasa Springett, President of Donatelle Plastics. “As a part of a broader healthcare offering, we will have even greater impact on patient outcomes by enabling the innovation and development of next generation devices for patients worldwide.”
